BeiGeneius Resources

Search results for all Resources:

BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Mantle cell lymphoma
 video   00:12:21   03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Mantle cell lymphoma
BeiGeneius - Highlights from ASH 2021: Practice-changing developments
 video   1:29:40   03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Aggressive lymphomas
 video   00:12:22   03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Aggressive lymphomas
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - CLL/SLL
 video   00:13:33   03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - CLL/SLL
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Indolent lymphomas
 video   00:13:48   03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Indolent lymphomas
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Q&A
 video   00:32:56   03/2022
BeiGeneius - Highlights from ASH 2021: Practice-changing developments - Q&A
BeiGeneius - Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?
 video   1:28:45   10/2021
BeiGeneius - Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?
Relapsed/refractory Waldenström
    09/2021
Relapsed/refractory Waldenström's macroglobulinaemia: Key considerations for managing pre-treated patients
BeiGeneius webinar #6 Save the Date
 pdf   09/2021
BeiGeneius webinar #6 Save the Date
BeiGeneius - Lymphoma management during the COVID-19 pandemic: New evidence-based insights and recommendations
 video   1:35:06   08/2021
BeiGeneius - Lymphoma management during the COVID-19 pandemic: New evidence-based insights and recommendations
BeiGeneius - Lymphoma management during the COVID-19 pandemic: New evidence-based insights and recommendations - Agenda
 pdf   07/2021
BeiGeneius - Lymphoma management during the COVID-19 pandemic: New evidence-based insights and recommendations - Agenda
What are the diagnostic considerations and clinical features for patients presenting with Waldenström’s macroglobulinemia symptoms?
 video   00:22:21   07/2021
What are the diagnostic considerations and clinical features for patients presenting with Waldenström’s macroglobulinemia symptoms?
What is Waldenström’s macroglobulinemia?
 video   00:03:49   07/2021
What is Waldenström’s macroglobulinemia?
Waldenström’s macroglobulinemia cell morphology
 video   00:03:33   07/2021
Waldenström’s macroglobulinemia cell morphology
The Waldenström’s macroglobulinemia-specific immunophenotype
 video   00:01:13   07/2021
The Waldenström’s macroglobulinemia-specific immunophenotype
The implication of genotypes in Waldenström’s macroglobulinemia
 video   00:04:07   07/2021
The implication of genotypes in Waldenström’s macroglobulinemia
Is it Waldenström’s macroglobulinemia, MGUS or IgM myeloma?
 video   00:01:25   07/2021
Is it Waldenström’s macroglobulinemia, MGUS or IgM myeloma?
Key diagnostic assessments when considering Waldenström’s macroglobulinemia
 video   00:01:27   07/2021
Key diagnostic assessments when considering Waldenström’s macroglobulinemia
Summary
 video   00:00:37   07/2021
Summary
Case study Diagnosing Waldenström’s macroglobulinemia: A patient’s journey
 video   00:20:36   07/2021
Case study Diagnosing Waldenström’s macroglobulinemia: A patient’s journey
Debate Should all patients undergo mutation analysis of MYD88 and CXCR4 as part of the Waldenström’s macroglobulinemia diagnostic work up?
 video   00:16:11   07/2021
Debate Should all patients undergo mutation analysis of MYD88 and CXCR4 as part of the Waldenström’s macroglobulinemia diagnostic work up?
Q&A What challenges do we face in diagnosing Waldenström’s macroglobulinemia?
 video   00:17:32   07/2021
Q&A What challenges do we face in diagnosing Waldenström’s macroglobulinemia?
Q&A When you have a high-quality bone marrow aspirate, is a bone marrow biopsy necessary for diagnosis?
 video   00:01:35   07/2021
Q&A When you have a high-quality bone marrow aspirate, is a bone marrow biopsy necessary for diagnosis?
Q&A How do you differentiate marginal zone lymphoma with IgM versus Waldenström’s macroglobulinemia?
 video   00:02:45   07/2021
Q&A How do you differentiate marginal zone lymphoma with IgM versus Waldenström’s macroglobulinemia?
Q&A Do you test for amyloidosis in the bone marrow biopsies of patients with Waldenström’s macroglobulinemia? Should this be done routinely for Waldenström’s macroglobulinemia patients or only when amyloidosis is suspected clinically?
 video   00:02:21   07/2021
Q&A Do you test for amyloidosis in the bone marrow biopsies of patients with Waldenström’s macroglobulinemia? Should this be done routinely for Waldenström’s macroglobulinemia patients or only when amyloidosis is suspected clinically?
What proportion of patients with Waldenström’s macroglobulinemia have neuropathy as their primary symptom? What is your favored treatment choice for neuropathy for patients with Waldenström’s macroglobulinemia?
 video   00:02:18   07/2021
What proportion of patients with Waldenström’s macroglobulinemia have neuropathy as their primary symptom? What is your favored treatment choice for neuropathy for patients with Waldenström’s macroglobulinemia?
Q&A How does a TP53 gene mutation affect your treatment strategy for a patient with Waldenström’s macroglobulinemia?
    07/2021
Q&A How does a TP53 gene mutation affect your treatment strategy for a patient with Waldenström’s macroglobulinemia?
Q&A What is your favored treatment for medically unfit elderly patients with Waldenström’s macroglobulinemia?
 video   00:01:15   07/2021
Q&A What is your favored treatment for medically unfit elderly patients with Waldenström’s macroglobulinemia?
Q&A Would you deny BTK inhibitor therapy to a Waldenström’s macroglobulinemia patient who is wild-type for MYD88 and CXCR4 genes?
 video   00:01:10   07/2021
Q&A Would you deny BTK inhibitor therapy to a Waldenström’s macroglobulinemia patient who is wild-type for MYD88 and CXCR4 genes?
Q&A Does Waldenström’s macroglobulinemia exist in association with production of immunoglobulins other than IgM, such as IgG or IgA? How are these patients treated?
 video   00:02:03   07/2021
Q&A Does Waldenström’s macroglobulinemia exist in association with production of immunoglobulins other than IgM, such as IgG or IgA? How are these patients treated?
Q&A Do you look at serum free light chain levels if there is amyloid in the bone marrow biopsy?
 video   00:01:08   07/2021
Q&A Do you look at serum free light chain levels if there is amyloid in the bone marrow biopsy?
BeiGeneius Steering Committe biographies
 pdf   07/2021
BeiGeneius Steering Committe biographies
BeiGeneius webinars 1+2, Q&A
 pdf   07/2021
BeiGeneius webinars 1+2, Q&A
BeiGeneius Bulletin Issue 2
 pdf   07/2021
BeiGeneius Bulletin Issue 2
BeiGeneius Bulletin Issue 3
 pdf   07/2021
BeiGeneius Bulletin Issue 3
BeiGeneius webinar #4 Save the Date
 pdf   07/2021
BeiGeneius webinar #4 Save the Date
BeiGeneius webinar 4 invitation letter
 pdf   07/2021
BeiGeneius webinar 4 invitation letter
BeiGeneius webinar #3 Q&A
 pdf   07/2021
BeiGeneius webinar #3 Q&A
Multidisciplinary management of Waldenström’s macroglobulinemia: The hematologist’s perspective
 video   21:29   05/2021
Multidisciplinary management of Waldenström’s macroglobulinemia: The hematologist’s perspective
Diagnosis and management of peripheral neuropathies in Waldenström’s macroglobulinemia and related IgM disorders
 video   22:36   05/2021
Diagnosis and management of peripheral neuropathies in Waldenström’s macroglobulinemia and related IgM disorders
Cardiovascular toxicities associated with BTK inhibitors: A case study and review
 video   23:37   05/2021
Cardiovascular toxicities associated with BTK inhibitors: A case study and review
Discussion and audience Q&A
 video   24:55   05/2021
Discussion and audience Q&A
BeiGeneius - Multidisciplinary management of Waldenström’s macroglobulinemia: Providing specialist care beyond hematology
 video   01:38:08   05/2021
BeiGeneius - Multidisciplinary management of Waldenström’s macroglobulinemia: Providing specialist care beyond hematology
BeiGeneius - Relapsed/refractory Waldenström’s macroglobulinemia: Key considerations for managing pre-treated patients
 video   01:25:28   03/2021
BeiGeneius - Relapsed/refractory Waldenström’s macroglobulinemia: Key considerations for managing pre-treated patients
BeiGeneius - Initiation of treatment for Waldenström’s macroglobulinemia: Practical guidance for starting treatment and managing complications
 video   01:21:00   01/2021
BeiGeneius - Initiation of treatment for Waldenström’s macroglobulinemia: Practical guidance for starting treatment and managing complications
Challenges in the diagnosis, staging, and clinical work up of Waldenström’s macroglobulinemia (WM): A practical guide to current best practice The complete webcast.
 video   01:31:49   11/2020
Challenges in the diagnosis, staging, and clinical work up of Waldenström’s macroglobulinemia (WM): A practical guide to current best practice The complete webcast.